Literature DB >> 7855464

A direct, general approach based on isobolograms for assessing the joint action of drugs in pre-clinical experiments.

S G Machado1, G A Robinson.   

Abstract

Pharmacologists and other biologists frequently use methods based on the interpretation of isobolograms to quantify the extent of synergy or antagonism between drugs used in combination in pre-clinical studies. Most methods have been unsatisfactory from a statistical viewpoint, many because they have relied solely on visual evaluation, others because the methods have not taken into account the variability of the measurements. We describe a direct approach for quantifying the joint potency of two drugs, a central feature being the use of simple isobole models that lead directly to response surface models for the expected experimental outcomes. The approach is general in the sense that one can use it for discrete or continuous responses, different underlying probability distributions, linear or non-linear dose-response functions of the drugs used singly, and a variety of experimental designs. Our approach extends the suggestions made by Hewlett for measuring the joint potency of drugs, and is similar in spirit to the approaches proposed by Greco et al. and Weinstein et al. We describe the analysis of data from an in vitro experiment conducted to evaluate the efficacy of the antiviral drugs AZT and ddI used in combination.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7855464     DOI: 10.1002/sim.4780132202

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  16 in total

1.  Targeting SRC in mucinous ovarian carcinoma.

Authors:  Koji Matsuo; Masato Nishimura; Justin N Bottsford-Miller; Jie Huang; Kakajan Komurov; Guillermo N Armaiz-Pena; Mian M K Shahzad; Rebecca L Stone; Ju Won Roh; Angela M Sanguino; Chunhua Lu; Dwight D Im; Neil B Rosenshien; Atsuko Sakakibara; Tadayoshi Nagano; Masato Yamasaki; Takayuki Enomoto; Tadashi Kimura; Prahlad T Ram; Kathleen M Schmeler; Gary E Gallick; Kwong K Wong; Michael Frumovitz; Anil K Sood
Journal:  Clin Cancer Res       Date:  2011-07-07       Impact factor: 12.531

2.  Assessing interactions for fixed-dose drug combinations in tumor xenograft studies.

Authors:  Jianrong Wu; Lorraine Tracey; Andrew M Davidoff
Journal:  J Biopharm Stat       Date:  2012       Impact factor: 1.051

3.  Analysis of antimalarial synergy between bestatin and endoprotease inhibitors using statistical response-surface modelling.

Authors:  C S Gavigan; S G Machado; J P Dalton; A Bell
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

4.  Combination of proteasome and HDAC inhibitors for uterine cervical cancer treatment.

Authors:  Zhenhua Lin; Martina Bazzaro; Mei-Cheng Wang; Kwun C Chan; Shiwen Peng; Richard B S Roden
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

5.  Drug interaction: focusing on response surface models.

Authors:  Soo-Il Lee
Journal:  Korean J Anesthesiol       Date:  2010-05-29

6.  Assessment of an anti-alpha-toxin monoclonal antibody for prevention and treatment of Staphylococcus aureus-induced pneumonia.

Authors:  L Hua; J J Hilliard; Y Shi; C Tkaczyk; L I Cheng; X Yu; V Datta; S Ren; H Feng; R Zinsou; A Keller; T O'Day; Q Du; L Cheng; M Damschroder; G Robbie; J Suzich; C K Stover; B R Sellman
Journal:  Antimicrob Agents Chemother       Date:  2013-12-02       Impact factor: 5.191

7.  Inhibition of hepatitis C virus replication by arsenic trioxide.

Authors:  Der-Ren Hwang; Yuan-Chin Tsai; Jin-Ching Lee; Kuo-Kuei Huang; Ren-Kuo Lin; Chia-Hua Ho; Jeng-Min Chiou; Ying-Ting Lin; John T A Hsu; Chau-Ting Yeh
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

8.  Assessing interactions for fixed-dose drug combinations in subcutaneous tumor xenograft studies.

Authors:  Jianrong Wu
Journal:  Pharm Stat       Date:  2013-03-07       Impact factor: 1.894

9.  Inhibition of homologous recombination with vorinostat synergistically enhances ganciclovir cytotoxicity.

Authors:  Brendon Ladd; Jeffrey J Ackroyd; J Kevin Hicks; Christine E Canman; Sheryl A Flanagan; Donna S Shewach
Journal:  DNA Repair (Amst)       Date:  2013-11-11

10.  Targeting SRC and tubulin in mucinous ovarian carcinoma.

Authors:  Tao Liu; Wei Hu; Heather J Dalton; Hyun Jin Choi; Jie Huang; Yu Kang; Sunila Pradeep; Takahito Miyake; Jian H Song; Yunfei Wen; Chunhua Lu; Chad V Pecot; Justin Bottsford-Miller; Behrouz Zand; Nicholas B Jennings; Cristina Ivan; Gary E Gallick; Keith A Baggerly; David G Hangauer; Robert L Coleman; Michael Frumovitz; Anil K Sood
Journal:  Clin Cancer Res       Date:  2013-10-07       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.